ABSTRACT
Purpose
Lung cancer is the leading cause of cancer-related death worldwide. The efficacy of current systemic treatments is limited, with major side effects and only modest survival improvements. Aerosols routinely used to deliver drugs into the lung for treating infectious and inflammatory lung diseases have never been used to deliver monoclonal antibodies to treat lung cancer. We have shown that cetuximab, a chimeric anticancer anti-EGFR mAb, is suitable for airway delivery as it resists the physical constraints of aerosolization, and have evaluated the aerosol delivery of cetuximab in vivo.
Methods
We developed an animal model of lung tumor sensitive to cetuximab by injecting Balb/c Nude mice intratracheally with A431 cells plus 10 mM EDTA and analyzed the distribution, pharmacokinetics and antitumor efficacy of cetuximab aerosolized into the respiratory tract.
Results
Aerosolized IgG accumulated durably in the lungs and the tumor, but passed poorly and slowly into the systemic circulation. Aerosolized cetuximab also limited the growth of the mouse tumor. Thus, administering anticancer mAbs via the airways is effective and may limit systemic side effects.
Conclusion
Delivery of aerosolized-mAbs via the airways deserves further evaluation for treating lung cancers.
Similar content being viewed by others
REFERENCES
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.
Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80.
Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol. 2010;7(7):401–14.
Thatcher N. The place of targeted therapy in the patient management of non-small cell lung cancer. Lung Cancer. 2007;57 Suppl 2:S18–23.
Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, et al. Aerosolized chemotherapy. J Aerosol Med. 2008;21(1):61–70.
Rohrmann K, Staehler M, Haseke N, Bachmann A, Stief CG, Siebels M. Immunotherapy in metastatic renal cell carcinoma. World J Urol. 2005;23(3):196–201.
Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN, et al. Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007;13(4):1246–52.
Scolnik PA. mAbs: a business perspective. Mabs. 2009;1(2):179–84.
Reichert JM. Global antibody development trends. Mabs. 2009;1(1):86–7.
Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol. 2008;68(2):93–106.
Gerber DE, Choy H. Cetuximab in combination therapy: from bench to clinic. Cancer Metastasis Rev. 2010;29(1):171–80.
Maillet A, Congy-Jolivet N, Le Guellec S, Vecellio L, Hamard S, Courty Y, et al. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharm Res. 2007;25:1318–26.
Gagnadoux F, Pape AL, Lemarié E, Lerondel S, Valo I, Leblond V, et al. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J. 2005;26(4):657–61.
Lerondel S, Le Pape A, Sené C, Faure L, Bernard S, Diot P, et al. Radioisotopic imaging allows optimization of adenovirus lung deposition for cystic fibrosis. Hum Gene Ther. 2001;12:1–11.
Cézé N, Ternant D, Piller F, Degenne D, Azzopardi N, Dorval E, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. Ther Drug Monit. 2009;31(5):597–601.
Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, et al. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. Mabs. 2009;1(5):505–16.
Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm. 1999;14(6):451–63.
Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res. 2004;10(19):6487–501.
Kang Y, Omura M, Suzuki A, Oka T, Nakagami Y, Cheng C, et al. Development of an orthotopic transplantation model in nude mice that simulates the clinical features of human lung cancer. Cancer Sci. 2006;97(10):996–1001.
Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1(4):338–44.
Bivas-Benita M, Zwier R, Junginger HE, Borchard G. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm. 2005;61(3):214–8.
Cryan SA, Sivadas N, Garcia-Contreras L. In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev. 2007;59(11):1133–51.
Barrett T, Koyama Y, Hama Y, Ravizzini G, Shin IS, Jang BS, et al. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res. 2007;13(22 Pt 1):6639–48.
Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007;34(6):850–8.
Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm. 2008;23(2):158–71.
Ushiki T, Kizaka-Kondoh S, Ashihara E, Tanaka S, Masuko M, Hirai H, et al. Noninvasive Tracking of Donor Cell Homing by Near-Infrared Fluorescence Imaging Shortly after Bone Marrow Transplantation. PlosOne. 2010;5(6):e11114.
Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and solid tumor microenvironment. J Natl Cancer Inst. 2007;99(19):1441–54.
Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74.
Dumont JA, Low SC, Peters RT, Bitonti AJ. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs. 2006;20(3):151–60.
Bitonti AJ, Dumont JA. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev. 2006;58(9–10):1106–18.
Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med. 2002;196(3):303–10.
Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984;44(3):1002–7.
Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993;53(18):4322–8.
ACKNOWLEDGMENTS
This work was supported by grants from the Ligue Contre le Cancer, the Cancéropôle Grand-Ouest, Région Centre and the IFR “Imagerie fonctionelle”. A. Maillet was financed by SPLF, Pneumologie Développement and ARAIR. Laurent Guilleminault holds a fellowship from the Fondation pour la Recherche Médicale. We thank Hervé Leroux, Maryline Le Mée, Stéphanie Rétif, Georges Roseau and Julien Sobilo for their help with the animal studies and imaging. We are grateful to Dr. A. Courtois for providing the FITC-cetuximab. Many thanks to Pr. Francis Gauthier for his comments on the manuscript and to J.F. Tournamille from CHU Bretonneau, Tours. The English text was edited by Dr. Owen Parkes.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Figure S1
A431 implantation in lungs with and without EDTAto establish an animal model of ectopic lung tumor sensitive to cetuximab.A431 cells (2.5 × 106) in medium with or without 10 mM EDTA were gently infused into the main bronchus of the mice via a catheter. (PDF 11 kb)
Supplementary Figure S2
Evaluation of sprayed cetuximab affinity to EGFR. A431 cells were incubated with native cetuximab or microsprayer sprayed cetuximab. Cells were then incubated with FITC-cetuximab and analyzed by flow cytometry. Results of cells treated with native cetuximab are indicated as a black line and with microsprayer sprayed cetuximab as a gray line. (docx 110 kb)
Supplementary Figure S3
Absence of toxicity attributed to airways delivery of cetuximab in BALB/c mouse. BALB/c mice were treated with cetuximab via i.p or airways, or PBS in the presence of Tc99m during 5 weeks. A : Weight variation and leukocyte formulation of mouse. Results are expressed as median for each group. Stripped bars: lymphocytes, black bars: monocytes and white bars: granulocytes. B: Histological analysis conducted post-mortem on liver (i), ileum (ii), oesophagus (iii), skin (iv), lungs (v), spleen (vi), kidney (vii) and trachea (viii) in a mouse that received sprayed cetuximab. Images are representative of one animal out of 10. (docx 750 kb)
Supplementary Figure S4
Evaluation of Xenofluor750™-cetuximab affinity to EGFR. A431 cells were incubated with unlabelledcetuximab or Xenofluor750™- cetuximab. Cells were then incubated with FITC-cetuximab and analyzed by flow cytometry. Results of cells treated with unlabelledcetuximab are indicated as dashed line and with Xenofluor750™-cetuximab as solid line. (doc 54 kb)
Supplementary Figure S5
Administration of free Xenofluor750™ by airways (A) or i.v.(B). (PDF 812 kb)
Rights and permissions
About this article
Cite this article
Maillet, A., Guilleminault, L., Lemarié, E. et al. The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors. Pharm Res 28, 2147–2156 (2011). https://doi.org/10.1007/s11095-011-0442-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-011-0442-5